Monograph Details
|
|
Pain & Pyrexia
> Narcotic analgesics
|
|
MSIR ORAL SOLUTION CONCENTRATE |
| Manufacturer |
|
Purdue Pharma L.P. |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
Opioid. |
| Generic Name |
|
Morphine sulfate 20mg/mL. |
| Also |
• MSIR
• MSIR ORAL SOLUTION
|
| Indications |
|
Moderate to severe pain. |
| Children |
|
Not recommended. |
| Adults |
|
Individualize and periodically reevaluate dose. Usual: 5–30mg every 4 hrs as needed. Terminal illness: may give on fixed dosing schedule. Caps can be sprinkled on food or contents mixed with fluid (see literature). |
| Contraindications |
|
Impaired respiration. Asthma. Paralytic ileus. |
| Precautions |
|
Head injury. Increased intracranial pressure. Acute abdomen. Shock. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Drug abusers. Debilitated. Biliary tract surgery. Kyphoscoliosis. Acute pancreatitis. Convulsive disorders. Delirium tremens. Elderly. Pregnancy (Cat.C). Labor & delivery, nursing mothers: not recommended. |
| Interactions |
|
Potentiation with alcohol, CNS depressants. Do not use within 14 days of MAOIs. Severe hypotension with phenothiazines. Potentiates neuromuscular blockers. |
| Adverse Reactions |
|
Sedation, drowsiness, GI upset, constipation, urinary retention, respiratory depression, orthostatic hypotension, syncope, dysphoria, euphoria. |
| How Supplied |
Tabs, caps—100
Soln—120mL
Soln conc—30mL, 120mL (w. dropper) |
|
|
|
|
